Literature DB >> 2868857

Serum protein binding of a new oral cephalosporin, CL 284,635, in various species.

M Bialer, A P Tonelli, J D Kantrowitz, A Yacobi.   

Abstract

CL 284,635 is a new third generation oral cephalosporin. Its serum protein binding was investigated in the human, monkey, dog, rat, and rabbit. This study was performed by using an equilibrium dialysis and ultrafiltration method, using radiolabeled and cold CL 284,635. In humans, CL 284,635 was found to have a mean free fraction [fu = concentration of unbound (free) drug divided by total concentration of unbound plus bound to serum proteins] of 31.3 +/- 3.3% with no serum concentration dependency in a range of 0.5 to 26 micrograms/ml. The drug was mainly bound to albumin. In rabbits and monkeys the protein binding profile of CL 284,635 was found to be 36.1 +/- 2.3% and 33.9 +/- 1.5% with no serum concentration dependency. In rats and dogs a non-concentration-dependent fu was observed at serum concentrations ranging from 0.5 to 30 micrograms/ml. A gradual increase in fu values was observed at higher serum concentrations of CL 284,635. Overall, the protein binding profile of CL 284,635 was found to be different in the five investigated species. The protein binding of CL 284,635 in monkeys and rabbits was most similar to that in humans. These species differences in protein binding may have an impact on the disposition of the drug in different species.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868857

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

Review 1.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.

Authors:  W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

3.  Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog.

Authors:  M Bialer; V K Batra; J A Morrison; B M Silber; Z M Look; A Yacobi
Journal:  Pharm Res       Date:  1987-02       Impact factor: 4.200

Review 4.  Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.

Authors:  R N Brogden; D M Campoli-Richards
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.